© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 24, 2021
Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.
An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.
Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.
A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.
Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.
October 10, 2018
Daniel A. Pollyea, MD, MS, discusses how far the field of acute myeloid leukemia has come in the last 1 to 2 years.